Jeff Cranmer

Executive Editor, BioCentury; Host, BioCentury This Week podcast. Jersey boy happily ensconced in Cali. Dad. Iggles fan. Cats. @Princeton, @SAISHopkins alum.

[Jeff Cranmer @jeff_cranmer]

Europe's narrow path between the U.S. and China: Europe has an opening to become biotech's third pole, says Franck Le Deu in a BioCentury Guest Commentary, but only if it engages China while anchoring IP, manufacturing, development at home (open access): https://t.co/NS7WLaLWIZ

[John Cleese @JohnCleese]

Eureka!! Hope you all are enjoying the World Cup

[Jeff Cranmer @jeff_cranmer]

https://t.co/X6NyDlOavA

[Jeff Cranmer @jeff_cranmer]

U.S. government's decision to brand WuXi AppTec a Chinese military co signals Trump admin intends to treat life sciences as a national security front, says BioCentury's @steveusdin1. Bipartisan will in Washington to reduce U.S. dependence on China's biopharma sector is strong.

[Jeff Cranmer @jeff_cranmer]

More jitters in Washington as congressional concern grows over integration of China, U.S. biopharma. Legislation to limit in-licensing, add biotech to outbound investment controls pressures Trump to curtail biopharma engagement w China, says @steveusdin1 https://t.co/to6ox2lLuh

[Jeff Cranmer @jeff_cranmer]

@ThatEricAlper David Hasselhoff while he was mugging at paintings in Versailles

[Jeff Cranmer @jeff_cranmer]

China NMPA priority rev in gastric cancer for Innovent's arcotatug tavatecan (IBI343) --> world's 1st CLDN18.2 ADC to be accepted for regulatory review h/t @BioBonanos

[Jeff Cranmer @jeff_cranmer]

Atlas-to-therapy push by @AllenInstitute in neurodegeneration: Brain Health Accelerator, debuting with $400M, aims to turn cellular maps and disease data into precision gene therapies for neurodegeneration. Via @DanielleGolovin in @bioCentury: https://t.co/pO4EMsexnT

[Jeff Cranmer @jeff_cranmer]

@canoebrookbl Therapies from @Atarabio @moderna_tx @Replimune $AZN @Corcept @Outlooktx @DiscMedicine all appear to be moving forward after #FDA setbacks. Here's hoping more follow suit. Watching out 4 progress 4 $RGNX $QURE $SCYX $BHVN

[Jeff Cranmer @jeff_cranmer]

Biopharma companies, investors and patient advocates have grounds for believing that @US_FDA decisions under Makary, Prasad that appeared final a few months ago may be reversed, says @steveusdin1 https://t.co/soTo7BFeU4

[BioCentury @BioCentury]

On the latest #BioCenturyThisWeek podcast: advances from $RVMD $SMMT Akeso at #ASCO26, embracing China innovation & U.S. science under threat — a BioCentury podcast with @BioPharmaJosh @SteveUsdin1 @FishburnSimone @Jeff_Cranmer @LaurenMMartz https://t.co/xoVvOVoYS6

[Jeff Cranmer @jeff_cranmer]

.@WHOMB's Russell Vought has poured gas on the foundations of science. Pharma CEOs should demand that President Donald Trump take away the matches, writes @steveusdin1 (open access): https://t.co/V0zTZMb0zV

[Jeff Cranmer @jeff_cranmer]

If half the time spent on hysteria about China in the U.S. went to competing on merits, biotechs and patients would be much better served, write my colleagues @BioPharmaJosh & @FishburnSimone. Open access: https://t.co/rVcrBlUrx2

[BioCentury @BioCentury]

The latest #BioCenturyThisWeek podcast: #ASCO26 preview, U.S. China policy, ADC linkers. Plus: a proposal by @RepAuchincloss to modernize U.S. clinical trials. With @Jeff_Cranmer @SteveUsdin1 @FishburnSimone and colleagues https://t.co/7lyWtaqe13

[jardelito @jardelito]

isso é o tipo de coisa que eu compraria se eu tivesse dinheiro e um cachorro

[Jeff Cranmer @jeff_cranmer]

A bit of everything this week, as @LaurenMMartz talks Revolution & more #ASCO26 insights, Tierney Baum geeks out on new ADC linker tech & @steveusdin1 breaks down China hawks push to set up biotech barriers.

[BioCentury @BioCentury]

The latest #BioCenturyThisWeek podcast: #ASCO26 preview, U.S. China policy, ADC linkers. Plus: a proposal by @RepAuchincloss to modernize U.S. clinical trials. With @Jeff_Cranmer @SteveUsdin1 @FishburnSimone and colleagues https://t.co/7lyWtaqe13

[Jeff Cranmer @jeff_cranmer]

Hengrui's Frank Jiang told me that his co's 13-program deal with $BMY is its 1st co-devel/co-comm deal with a Western biopharma, “another critical milestone on Hengrui’s globalization journey.” From NewCos to GSK, H has done some of the most interesting cross-border deals of late

[Jeff Cranmer @jeff_cranmer]

Marty Makary won't be missed as @US_FDA commissioner, writes @steveusdin1. Now the Trump administration must decide whether and how to right the ship in the wake of his disastrous tenure https://t.co/hXgWiQ1kNZ

[Jeff Cranmer @jeff_cranmer]

@ThatEricAlper Dinosaur Jr. at Slim's.

[Jeff Cranmer @jeff_cranmer]

Top internal @US_FDA candidates for acting commissioner: Grace Graham, deputy commish for policy, legislation, international affairs; Lowell Zeta, deputy commish for strategic initiatives; Kyle Diamantas, deputy commish for human foods. via @Steveusdin1 https://t.co/yGGYdLFOfV